ResMed’s SERVE-HF Phase III Trial Did Not Meet Primary Endpoint
ResMed’s SERVE-HF—a multinational, multicenter, randomized controlled Phase III trial—did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep...
Read More